CTI has unparalleled experience in working with complex and critically ill patients.

Hematology and oncology are growing areas of research with several new and innovative products in development over the last several years.

CTI has led projects across the spectrum of hematology and oncology research including complex and rare diseases.

CTI’s expertise includes a Medical Affairs team with a background in hematological malignancies and stem cell transplantation as well as an oncologist, all of which work closely with the rest of our organization so that project teams are familiar with these often complex and critically ill patients. We have managed projects involving adult, pediatric, and neonate populations on clinical trials, educational programs, and regulatory consulting. Past and ongoing trials have ranged from small first-in-human trials to large expanded access programs (EAPs).

We have been involved in the development of numerous products in these areas, including the recently approved Voraxaze®. We also routinely attend industry meetings focused on hematology and oncology, including the American Society for Hematology annual meetings (ASH).

We offer our sponsors:

infinity symbol

Immuno-oncology

Immuno-oncology is the frontier of personalized medicine, and it is an area CTI excels in. Approximately 30% of CTI's most recent programs are in oncology and cell therapy, and over half of our recent projects are deeply rooted in immunological indications. Our approach has stayed true to our therapeutic focus and clinical trial expertise. We focus in complex and critically ill patient populations, bringing a huge reservoir of immunology and cellular therapy expertise to these programs.

Some of our adult and pediatric experience includes:

  • 5-Fluorouracil toxicity
  • Advanced cholangiocarcinoma (advanced bile duct cancer)
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Advanced solid tumors
  • B cell lymphomas
  • Beta-thalassemia
  • Bladder cancer
  • Breast cancer
  • Brain tumors
  • C3-glomerulopathy (C3G)
  • Cervical cancer
  • Chronic myelogenous leukemia (CML)
  • Coagulation (bleeding disorders)
  • Diffuse Intrinsic Pontine Glioma (DIPG)
  • Gastric / gastroesophageal cancer
  • Glioblastoma (GBM)
  • Graft versus host disease (GVHD)
  • Head-and-neck cancer
  • Hemochromatosis
  • Hematological malignancies
  • Hepatocellular carcinoma
  • Heparin-induced thrombocytopenia (HIT)
  • High Grade Gliomas (HGGs)
  • Hodgkin’s lymphoma
  • Leukemias
  • Lymphoma
  • Melanoma
  • Methotrexate toxicity (MTX)
  • Myeloma
  • Neuro-oncology
  • Non-hodgkin’s lymphomas (NHLs)
  • Non-small cell lung cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • Pediatric malignancies
  • Post-surgical bleeding
  • Prostate cancer
  • Rare cancers
  • Sarcoma
  • Sickle cell (SCD)
  • Solid tumors
  • Stem cell transplant (SCT)
  • Various hemaglobinopathies
  • Wound healing